로그인|회원가입|고객센터|기업교육 문의
페이지 맨 위로 이동
검색

Medical / Research

Korean Researchers Propose New Strategy to Boost NK Cells

Dong-A Ilbo | Updated 2026.10.13
From left, Professor Yoon Mi-seon of the Department of Radiation Oncology at Chonnam National University Hwasun Hospital, Dr. Tung Ung, and Professor Cho Deok of the Department of Laboratory Medicine at Samsung Medical Center. Courtesy of Chonnam National University Hwasun Hospital

A Korean research team has identified a new treatment method that removes the “inhibitory switch” inside immune cells to dramatically enhance the efficacy and durability of immunotherapies that attack cancer cells.

The joint research team led by Professor Yoon Mi-seon of the Department of Radiation Oncology at Chonnam National University Hwasun Hospital and Professor Cho Deok of the Department of Laboratory Medicine at Samsung Medical Center announced on the 12th that it had identified the mechanism of action of the protein “PTPN22,” which reduces anticancer function inside one type of immune cell, the “NK cell (natural killer cell),” and developed a technology to control it.

NK cells are representative immune cells in the body that autonomously locate and destroy cancer cells. Recently, research has been actively conducted on “next-generation immune cell therapies (CAR-NK)” that genetically engineer NK cells so they can attack cancer cells more precisely and powerfully.

?However, existing immunotherapies have had the limitation that their cytotoxic activity declines over time when exposed to the harsh immunosuppressive environment surrounding cancer cells.

The research team used gene-editing technology to remove the “PTPN22” protein, which exerts an immunosuppressive effect inside NK cells, and then measured the anticancer effect. As a result, NK cells lacking PTPN22 showed a substantial enhancement in their cancer cell-killing capacity and maintained their anticancer function for a much longer period even in an immunosuppressive environment.

This functional enhancement was observed not only in general hematologic malignancies but also in CAR-NK therapies targeting solid tumors, which are particularly difficult to treat.

In actual animal experiments, administration of CAR-NK cells with PTPN22 removed effectively suppressed the proliferation of leukemia cells and significantly extended the survival period of the test animals.

The research team explained that, unlike conventional immunotherapies that mainly modulated cell-surface receptors, this study is highly significant in that it overcomes the limitations of immune cells by directly targeting and blocking an intracellular regulatory factor (PTPN22).

Professor Yoon stated, “PTPN22 is an intracellular immune brake that had been limiting the cytotoxic activity of NK cells,” adding, “This study will serve as a useful strategy to simultaneously enhance the anticancer efficacy and treatment durability of next-generation immune cell therapies.”

The results of this study were published in the Journal for ImmunoTherapy of Cancer, a leading international journal in the field of cancer immunotherapy, and the research team has completed patent registration for the related core technology.

Lee Jin-han

AI-translated with ChatGPT. Provided as is; original Korean text prevails.
Popular News

경영·경제 질문은 AI 비서에게,
무엇이든 물어보세요.

Click!